Clinical Trial

A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice

Active, Not Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The primary purpose of this study is to evaluate the efficacy of filgotinib in establishing clinical remission at Week 10 or 22.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-03
Trial Details
NCT Number NCT06964113
Lead Sponsor Eisai Korea Inc.
Collaborators: Gilead Sciences
Conditions Ulcerative Colitis
Enrollment 94 participants
Start Date 2025-06-11
Primary Completion 2027-11-30 (estimated)
Study Completion 2027-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-07-02